Posted by Michael Wonder on 17 Oct 2022
Biogen announces FDA’s 3 month extension of review period for the new drug application for tofersen
17 October 2022 - The new Prescription Drug User Fee Act action date set by the FDA is 25 April 2023.
Biogen today announced that the US FDA has extended the review period of the new drug application for tofersen by three months.
